Market Overview

Chardan Capital Initiates Lion Biotechnologies With Buy


Analysts at Chardan Capital initiated coverage on Lion Biotechnologies Inc (NASDAQ: LBIO) with a Buy rating.

The target price for Lion Biotechnologies is set to $30.

Lion Biotechnologies shares have gained 40.35 percent over the past 52 weeks, while the S&P 500 index has surged 12.25 percent in the same period.

Lion Biotechnologies' shares rose 4.23 percent to $12.58 in pre-market trading.

Latest Ratings for LBIO

Mar 2017Wells FargoInitiates Coverage OnOutperform
Apr 2015Chardan CapitalInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform

View More Analyst Ratings for LBIO
View the Latest Analyst Ratings


Related Articles (LBIO)

View Comments and Join the Discussion!

Posted-In: Chardan CapitalInitiation Analyst Ratings

Latest Ratings

HYMCBMO CapitalInitiates Coverage On
DEMorgan StanleyMaintains335.0
SBNYRaymond JamesMaintains138.0
CORTHC Wainwright & Co.Maintains32.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at